Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming its blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight. Though trials are still in their early stages, Novo Nordisk (NYSE:NVO) hopes it can add another killer app to its portfolio of weight-loss drugs. The successes of Wegovy and Novo Nordisk’s other injection-based obesi ...

ToplineShares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company’s plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.Early data on the pill suggested it may outperform Wegovy, an injectable prescription weight loss ... [+] medicine.UCG/Universal Images Group via Getty Images ...

Novo Nordisk (NVO) announced top-line data from the kidney outcomes study, FLOW, evaluating the efficacy of Ozempic (semaglutide) as an adjunct to standard of carefor the prevention of the progression of renal impairment in people with type II diabetes (T2D) and chronic kidney disease (CKD) compared with placebo.Per the data readout, the FLOW outcomes study achieved its primary endpoint of a superior reduction of 24% in kidney disease progression, as well as cardiovascular and kidney death for people treate ...

High-flying healthcare stock Novo Nordisk (NVO -2.58%) lost a bit of altitude on Tuesday, following its latest news from the laboratory. A clinical trial wasn't quite as successful as hoped, and investors expressed their displeasure by trading out of the Danish company's shares. At the end of the day, the stock had lost nearly 3% of its value, comparing unfavorably to the 1% decline of the benchmark S&P 500 index.A clinical trial fell short of expectationsNovo Nordisk is busy developing semaglutide, sold un ...

The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NVO -2.49%), thanks to its type 2 diabetes medicine Ozempic and the Wegovy version approved for weight loss. However, Ozempic and Wegovy are facing stiff competition, notably from Mounjaro and Zepbound, marketed by Novo Nordisk's eternal rival, Eli Lilly. Further, a little-known but highly promising biotech is also looking to challenge Novo Nor ...

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo. Around 40% of people with type 2 diabetes have chronic kidney disease. It stopped the trials on 3,533 people a full year before it was mean ...

This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France.Novo Nordisk's blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday. Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compa ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment opportunities in 2024. Investors are drawn to the biotech industry not only for their potential to deliver substantial profits, but for the promise of contributing to medical breakthroughs. This can be achieved by the larger pharmaceutical giants or smaller biotechnology startups pioneering therapies like gene-editi ...

Key PointsWhile known for chicken, Tyson Foods is the largest beef producer in the United States, with over $5 billion in quarterly sales for fiscal Q1 2024.Tyson Foods sells its beef and pork under brands including Chairman's Reserve Meats, Star Ranch Angus Beef, ibp Trusted Excellence Brand, Reuben Corned Beef and Open Prairie Natural Pork.Pilgrim's Pride is one of the largest chicken producers in the world, reporting a strong Q4 2023, beating EPS estimates by 16 cents, with revenues climbing 9% YoY to $4 ...